Renal function and laboratory safety parameters after two weeks' administration of fluproquazone to man.
When 4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone (fluproquazone) was given for 14 days (100 mg t.i.d.) to six healthy male volunteers, it produced no clinically relevant effects upon the subjects' renal function, urine microscopic findings, blood coagulation status, or upon their general well-being as shown by a range of laboratory safety tests including haematological profile and blood and urine biochemistry. Minor and transient side effects mainly affecting the gastrointestinal system were seen in four subjects.
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000633:toxicity*; D001774:Blood Chemical Analysis; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000097:blood / Q000633:toxicity*; D052999:Quinazolinones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011799:Quinazolines; D052999:Quinazolinones; C023491:fluproquazone